PT  - JOURNAL ARTICLE
AU  - Walter Vincken
AU  - Joseph Aumann
AU  - Pankaj Goyal
AU  - Pablo Altman
TI  - Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P2410
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P2410.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P2410.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - IntroductionThe GLOW6 study reported rapid onset and sustained bronchodilation with co-administration of indacaterol (IND) and glycopyrronium (GLY) compared to IND alone in patients (pts) with COPD.1 In this post-hoc analysis, we compared the effect of free combination use of GLY+IND+ICS vs IND+ICS on lung function and dyspnoea in a sub-group of pts using ICS during the study.MethodsThe 12-week, multicentre, double-blind, parallel group GLOW6 study randomised 449 symptomatic pts with moderate-to-severe COPD to GLY+IND or IND alone. 132 (29.4%) pts had ≥1exacerbations in the year prior to randomisation. 280 (62.6%) pts were on stable dose of ICS at baseline and were allowed to continue ICS during the study. We analysed this subgroup comparing free combination GLY+IND+ICS vs IND+ICS for improvements in trough FEV1, FEV1 area under the curve from 0 to 4h (AUC0-4h), and transition dyspnoea index (TDI).ResultsOf the 280 pts, 138 were on GLY+IND+ICS and 142 on IND+ICS. Compared to free combination of IND+ICS, free combination of GLY+IND+ICS significantly improved trough FEV1 (mean treatment difference [MTD] 64ml; p=0.021) at Wk12, FEV1 AUC0-4h on Day1 (MTD 111ml; p<0.001) and at Wk12 (MTD 118ml; p<0.001) and dyspnoea in terms of TDI score (MTD 0.7; p=0.041).ConclusionOver 12 wks, the free triple combination (GLY+IND+ICS) showed significantly better improvements in lung function and dyspnoea compared to the free double combination (IND+ICS) in symptomatic pts with moderate-to-severe COPD.Reference1. Vincken W, et al. Int J Chron Obstruct Pulmon Dis 2013 [In press].